31 / 38
Drug(s)
Biology Systemic
activity
CNS
activity
Modest
toxicity
PFS
benefit
OS
benefit
Osimertinib
Dacomitinib
Unknown
Afatinib
Erlotinib/Bev
acizumab
Unknown
Gefitinib/Che
motherapy
Unknown
How to choose the best front line therapy
for metastatic
EGFR
mutant NSCLC